HC Wainwright & Co. Maintains Buy on TG Therapeutics, Lowers Price Target to $70
HC Wainwright & Co. analyst Edward White maintains TG Therapeutics (NASDAQ:TGTX) with a Buy and lowers the price target from $75 to $70.
TG Therapeutics Highlights ASH Presentation
TG Therapeutics, Inc. (NASDAQ:TGTX), today announced two data presentations, highlighted data from the UNITY-CLL Phase 3 trial evaluating the combination of ublituximab, the Company's investigational anti-CD20
Cramer Gives His Opinion On GlaxoSmithKline, Asana And More
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Penn National Gaming, Inc. (NASDAQ: PENN) has been crushed, but selling the stock right now is a mistake.
Goldman Sachs Maintains Sell on TG Therapeutics, Lowers Price Target to $13
Goldman Sachs maintains TG Therapeutics (NASDAQ:TGTX) with a Sell and lowers the price target from $26 to $13.
HC Wainwright & Co. Maintains Buy on TG Therapeutics, Lowers Price Target to $75
HC Wainwright & Co. analyst Edward White maintains TG Therapeutics (NASDAQ:TGTX) with a Buy and lowers the price target from $84 to $75.
Mid-Afternoon Market Update: Dow Dips 500 Points; ImmunoGen Shares Spike Higher
Toward the end of trading Tuesday, the Dow traded down 1.44% to 34,628.69 while the NASDAQ fell 1.34% to 15,571.16. The S&P also fell, dropping 1.36% to 4,592.03.
TG Therapeutics Shares Plunge After FDA Plans AdComm Meet For Blood Cancer Candidate
TG Therapeutics Inc (NASDAQ: TGTX) shares are falling after FDA notified the Company that it plans to host an Oncologic Drugs Advisory Committee (ODAC) meeting for marketing application regarding ublituximab/ Ukoniq (umbralisib) (U2 combo).